Canaccord Genuity Maintains Buy on Definitive Healthcare, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst David Hayes maintains a 'Buy' rating on Definitive Healthcare (NASDAQ:DH), but has lowered the price target from $13 to $12.

August 15, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Definitive Healthcare's price target has been lowered from $13 to $12 by Canaccord Genuity, though the 'Buy' rating is maintained.
The lowering of the price target by Canaccord Genuity could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintenance of the 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100